Our findings indicate that NASH patients treated with OCA experienced statistically significant reductions in biochemical indicators such as ALT, AST, ALP, and GGT, compared to those treated with a placebo. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.